GV and Alexandria Venture Investments have taken part in a $191m funding round to launch Maze Therapeutics with scientific co-founders from multiple universities such as Harvard and Stanford.

University of Virginia spectroscopy spinout BrightSpec has added series B capital from investors including the university's seed fund to an earlier $1.5m sum raised in 2015.

The UC Berkeley-founded MRI scanner technology spinout graduated from the SkyDeck accelerator in 2018 and has now announced its inaugural round of funding.

Karolinska Institute’s oncology spinout Aprea Therapeutics has received a $5.7m series C extension adding to an initial $56.8m close in November 2018 that featured Karolinska Development.

Praktikertjänst-backed oncology company Aprea has received a $5.7m series C extension adding to an initial $56.8m close in November 2018 that featured Karolinska Development.

Rabo Ventures has co-led the artificial intelligence-based medical imaging technology developer's $11.3m series A alongside Inkef Capital.

Satt Sud-Est has licensed Yukin Therapeutics to commercialise patents originating from several French institutions on the back of inventions from regional research hub Canceropôle Provence-Alpes-Côte d'Azur.

Blackstone Life Sciences and Novartis have launched Anthos Therapeutics, with the former putting in $250m and Novartis licensing one of its assets to the startup.

Immunotherapy developer Hookipa, backed by Gilead, Boehringer Ingelheim and Takeda, has collected $37.5m in a series D round led by Redmile Group.

Zurich immuno-oncology spinout Anaveon raised $35.1m from Novartis Venture Fund and Syncona in addition to seed-stage notes converted by the UZH Life Sciences Fund.